• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Aerami presents positive data for inhaled pulmonary hypertension treatment

May 24, 2023 By Sean Whooley

aerami-therapeuticsAerami Therapeutics today announced positive data supporting its inhaled imatinib for treating pulmonary hypertension (PH).

Studies of AER-901 support progression into a Phase 2 clinical trial. Data backed Aerami’s treatment for both PH associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

AER-901 is a drug-device combination. Aerami designed it to deliver potentially reverse-remodeling imatinib therapy deeply and efficiently throughout diseased tissue of the lung. Delivery takes place through a high-performance, handheld, smart nebulizer. It controls flow rates and provides patients with real-time feedback to optimize lung deposition.

Aerami presented data at the 2023 American Thoracic Society (ATS) International Conference. Findings included pharmacokinetic outcomes in rats receiving a single dose of oral imatinib mesylate or pulmonary administration of AER-901.

About the Aerami study

Key findings demonstrated nearly 10-fold higher lung exposure with pulmonary administration compared with equivalent oral imatinib. By targeting the lung, data suggests the effective AER-901 dose is potentially 10 times lower than the original oral dose, according to a news release. Standard oral doses studied in PH total between 200 mg and 400 mg.

The completed Phase 1 trial evaluated the safety, tolerability and pharmacokinetics of low inhaled doses. It compared those doses to placebo in more than 80 participants. The study included single and multiple ascending dose studies, evaluating doses from 5 mg to 80 mg, Aerami said.

AER-901 demonstrated a predominantly mild and transient adverse event profile consistent with inhalation products, the company said. Cough and throat irritation — consistent with inhaled products — constituted the most frequent adverse events.

Aerami wants AER-901 to address a “critical unmet medical need” for people with the serious and rare forms of PH. The company plans to update its open investigational new drug (IND) application with the FDA. It aims to initiate a Phase 2 proof-of-concept clinical trial in mid-2023.

“These important data presented at ATS and the full results of Aerami’s completed Phase 1 of AER-901 study mark significant steps forward in the development of AER-901 with the ultimate goal of addressing the critical unmet medical need for patients with PH-ILD and PAH,” said Anne Whitaker, executive chair of the board of directors at Aerami. “The positive results strongly support our path forward into Phase 2.”

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: Aerami Therapeutics

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS